Cost-effectiveness of first-line sintilimab plus chemotherapy versus chemotherapy for advanced esophageal carcinoma in China
Compared with chemotherapy alone, sintilimab may be a cost-effective first-line treatment choice for locally advanced or metastatic ESCC.
Authors
- Shiting Chen (ORCID: https://orcid.org/0000-0003-2104-1779)
- Nanlong Lin
- Zhiwei Zheng
- Xiaobing Song
Institutions
- Fujian Medical University (CN)
- Shantou University (CN)
- Cancer Hospital of Shantou University Medical College (CN)
- Ganzhou People's Hospital (CN)
- First Affiliated Hospital of Fujian Medical University (CN)
- The Fifth People’s Hospital of Suzhou (CN)
Publication Details
- Journal
- Expert Review of Pharmacoeconomics & Outcomes Research
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1080/14737167.2024.2410248
- Primary Topic
- Esophageal Cancer Research and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Guangdong Medical Research Foundation